2型糖尿病の治療効果における年齢と性別の違い:ネットワークメタ解析
Peter Hanlon1, Elaine Butterly1, Lili Wei1
1School of Health and Wellbeing, University of Glasgow, Glasgow, Scotland.
JAMA
|February 3, 2025
まとめ
2型糖尿病では,ナトリウム・グルコース・コトランスポーター2 (SGLT2) 阻害剤とグルカゴン類ペプチド1 (GLP-1) 受容体アゴニストが心血管疾患を軽減する. SGLT2阻害剤は高齢者に対して心臓保護効果が高く,GLP- 1アゴニストは若者に対して効果が異なる.
科学分野:
- 内分泌学と代謝
- 心血管疾患の研究
- 薬理学について
背景:
- 2型糖尿病における高血糖症の治療には,ナトリウム・グルコース・コトランスポーター2 (SGLT2) 阻害剤,グルカゴン型ペプチド-1 (GLP-1) 受容体アゴニスト,ディペプチジルペプチダゼ4 (DPP4) 阻害剤が確立されています.
- SGLT2阻害剤とGLP-1受容体アゴニストは,主要な心血管疾患 (MACE) の減少に有益であることが示されています.
- しかし,これらの薬剤の有効性に対する患者の年齢と性の影響は,まだ完全に理解されていません.
研究 の 目的:
- 2型糖尿病の成人のSGLT2阻害剤,GLP-1受容体アゴニスト,DPP4阻害剤の効能に年齢や性別が影響するかどうかを調べる.
- 血糖値制御 (HbA1c) と心血管のアウトカム (MACE) に関する年齢と性との相互作用を分析する.
主な方法:
- MEDLINE,Embase,および臨床試験の登録を2022年11月まで体系的に検索し,2024年8月に更新しました.
- SGLT2阻害剤,GLP-1受容体アゴニスト,またはDPP4阻害剤とプラセボまたは2型糖尿病の成人を比較したランダム化臨床試験が含まれていた.
- 年齢 × 治療と性別 × 治療の相互作用を評価するために,複数のレベルのネットワークメタレグレッションモデルを使用して,個々の参加者データと集約データを分析した.
主要な成果:
- 103件の試験 (HbA1cを報告した) と6件の試験 (MACEを報告した) の個々の参加者データを分析した.
- SGLT2阻害剤は,年齢とともにHbA1cの低下が少なく,高齢者ではMACEの減少が大きいことを示した.
- GLP- 1受容体アゴニストは,単療法と二重療法では年齢とともにHbA1cの低下が顕著であったが,若い個体ではより心臓保護的であった.
- DPP4阻害剤は,高齢者において,HbA1cの低下をわずかに改善した.
- SGLT2阻害剤やGLP-1受容体アゴニストについては,性 × 治療による一貫した相互作用は観察されなかった.
結論:
- SGLT2阻害剤とGLP-1受容体のアゴニストは,年齢に依存する効果で,タイプ2糖尿病におけるMACEを効果的に減少させる.
- SGLT2阻害剤は高齢患者でより心臓保護的であり,GLP-1受容体アゴニストは若い患者でより大きな効果を示しています.
- 2型糖尿病における心血管疾患のリスクを減らすためにこれらの薬物を選択する際に年齢を考慮する重要性を強調しています.
関連する概念動画
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Diabetes: Management and Pharmacotherapy
232
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
232
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Insulin: Dosing Regimen and Adverse Effects
141
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
141
Oral Hypoglycemic Agents: Biguanides and Glitazones
162
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
162
Carbohydrate Metabolism
10.7K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.7K


